NASDAQ · LICN
Lichen China Limited financials
$1.02−0.97%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 |
|---|---|---|---|
| Revenue | $24.5M | $41.5M | $39.8M |
| Gross profit | $9.1M | $25.7M | $24.3M |
| Gross margin | 37.3% | 61.9% | 61.2% |
| Operating income | -$18.1M | -$4.6M | $12.3M |
| Net income | -$22.0M | -$6.1M | $8.3M |
| Net margin | −89.6% | −14.8% | 21.0% |
| Diluted EPS | $-4.14 | $-34.90 | $63.96 |
| EBITDA | -$10.2M | -$1.7M | $15.2M |
| Operating cash flow | -$17.8M | -$5.6M | $557.0K |
| Free cash flow | -$17.8M | -$5.7M | -$2.6M |
| Diluted shares | 5.3M | 0.2M | 0.1M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|
| Cash & equivalents | $26.9M | $26.7M | $25.9M |
| Short-term investments | $0.00 | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 |
| Total assets | $75.6M | $79.8M | $65.5M |
| Total liabilities | $5.0M | $4.3M | $4.1M |
| Shareholders' equity | $70.5M | $75.6M | $61.4M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology